Epizyme Cash on Hand 2012-2022 | EPZM

Epizyme cash on hand from 2012 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Epizyme Annual Cash on Hand
(Millions of US $)
2021 $177
2020 $374
2019 $381
2018 $240
2017 $276
2016 $242
2015 $208
2014 $190
2013 $124
2012 $98
2011 $33
Epizyme Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $200
2021-12-31 $177
2021-09-30 $221
2021-06-30 $244
2021-03-31 $299
2020-12-31 $374
2020-09-30 $280
2020-06-30 $322
2020-03-31 $376
2019-12-31 $381
2019-09-30 $293
2019-06-30 $331
2019-03-31 $371
2018-12-31 $240
2018-09-30 $181
2018-06-30 $216
2018-03-31 $248
2017-12-31 $276
2017-09-30 $307
2017-06-30 $193
2017-03-31 $211
2016-12-31 $242
2016-09-30 $263
2016-06-30 $289
2016-03-31 $313
2015-12-31 $208
2015-09-30 $230
2015-06-30 $237
2015-03-31 $245
2014-12-31 $190
2014-09-30 $212
2014-06-30 $230
2014-03-31 $237
2013-12-31 $124
2013-09-30 $140
2013-06-30 $149
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2011-12-31 $33
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.244B $0.037B
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00